Experts warn that the surge in demand for weight loss injections like Ozempic and Wegovy is unsustainable, with most users ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

The top-line outcomes from SUPREME-01 are anticipated between the fourth quarter of 2026 and the first quarter of 2027.

Caliway receives US FDA clearance to proceed with SUPREME-01 phase 3 study of CBL-514 for reducing abdominal subcutaneous fat: New Taipei City Tuesday, July 29, 2025, 14:00 Hrs [I ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...